The restricted stock units are set to vest over a three-year period, with one-third of the total award maturing on each consecutive anniversary of the grant date. This schedule remains contingent upon the employee maintaining continuous service with the company throughout the duration of the vesting cycle. The award was issued through the firm's 2022 Inducement Stock Incentive Plan, a mechanism specifically designed to attract new talent through equity-based compensation.
Karyopharm Therapeutics Issues Inducement Grant to New Hire
Karyopharm Therapeutics has issued 333 restricted stock units to a newly hired employee, marking a targeted compensation move under Nasdaq Listing Rule 5635(c)(4). The grant, finalized on July 31, 2026, serves as a material incentive for the recruit to join the Massachusetts-based pharmaceutical firm.
Karyopharm, headquartered in Newton, currently focuses on nuclear export inhibition, with its primary therapy XPOVIO approved for treating relapsed or refractory multiple myeloma. The company continues to advance its clinical pipeline, exploring the efficacy of selinexor and next-generation compounds like eltanexor in addressing various hematological cancers and myeloproliferative neoplasms.
Comments (0)
No comments yet. Be the first!